Checkpoint blockade for cancer therapy: Revitalizing a suppressed immune system

Trends in Molecular Medicine

Volumn 21, Issue 8, 2015, Pages 482-491

  Pico de Coaña, Yago ^a   Choudhury, Aniruddha ^b   Kiessling, Rolf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cancer immunotherapy; Checkpoint blockade; CTLA 4; MDSCs; PD 1

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; LIGAND;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; DENDRITIC CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; RADIOTHERAPY; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LIGANDS; MOLECULAR TARGETED THERAPY; MYELOID CELLS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIOTHERAPY; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 84938547904     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.05.005     Document Type: Review

References (104)

1. Kitai H., et al. Spontaneous regression of small cell lung cancer combined with cancer associated retinopathy. Lung cancer 2015, 87:73-76.
2. Printz C. Spontaneous regression of melanoma may offer insight into cancer immunology. J. Natl. Cancer Inst. 2001, 93:1047-1048.
3. Lee P.P., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 1999, 5:677-685.
4. Clark W.H., et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 1989, 81:1893-1904.
5. Gao Q., et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 2007, 25:2586-2593.
6. Zhang L., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.
7. Parmar S., Ritchie D.S. Allogeneic transplantation as anticancer immunotherapy. Curr. Opin. Immunol. 2014, 27:38-45.
8. Deol A., Lum L.G. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat. Rev. 2010, 36:528-538.
9. Dudley M.E., Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 2003, 3:666-675.
10. Brunet J.F., et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987, 328:267-270.
11. Attia P., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005, 23:6043-6053.
12. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
13. Gelao L., et al. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an 'innocent bystander'. Toxins 2014, 6:914-933.
14. Bretscher P., Cohn M. A theory of self-nonself discrimination. Science 1970, 169:1042-1049.
15. June C.H., et al. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell. Biol. 1987, 7:4472-4481.
16. Thompson C.B., et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:1333-1337.
17. van der Merwe P.A., et al. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J. Exp. Med. 1997, 185:393-403.
18. Egen J.G., Allison J.P. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002, 16:23-35.
19. Blazar B.R., et al. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J. Immunol. 1999, 162:6368-6377.
20. + T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases. J. Immunol. 2002, 168:4420-4429.
21. Wang X.B., et al. CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation. BMC Immunol. 2011, 12:21.
22. + adaptive regulatory T cells. J. Immunol. 2007, 179:5191-5203.
23. Grohmann U., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 2002, 3:1097-1101.
24. Pico de Coaña Y., et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol. Res. 2013, 1:158-162.
25. Tarhini A.A., et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS ONE 2014, 9:e87705.
26. Meyer C., et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 2014, 63:247-257.
27. Pico de Coaña Y., et al. Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy. Cancer Immunol. Immunother. 2014, 63:977-983.
28. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 2007, 19:813-824.
29. Sharpe A.H., et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 2007, 8:239-245.
30. Nurieva R.I., et al. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol. Rev. 2009, 229:88-100.
31. Freeman G.J., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
32. Ou J.N., et al. TNF-alpha and TGF-beta counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. Sci. Rep. 2012, 2:295.
33. Okazaki T., et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 2013, 14:1212-1218.
34. Phan G.Q., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8372-8377.
35. Waterhouse P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988.
36. Tivol E.A., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
37. Nishimura H., et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
38. Nishimura H., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291:319-322.
39. Francisco L.M., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009, 206:3015-3029.
40. Mougiakakos D., et al. Regulatory T cells in cancer. Adv. Cancer Res. 2010, 107:57-117.
41. Duraiswamy J., et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013, 73:3591-3603.
42. Ribas A., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 2013, 31:616-622.
43. Calabro L., et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013, 14:1104-1111.
44. Robert C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
45. Schadendorf D., et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 2015, Published online February 9, 2015. http://dx.doi.org/JCO.2014.56.2736.
46. Hodi F.S., et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. Jama 2014, 312:1744-1753.
47. Eggermont A.M., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015, 16:522-530.
48. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
49. Topalian S.L., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 2014, 32:1020-1030.
50. Hamid O., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369:134-144.
51. Robert C., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372:320-330.
52. Weber J.S., et al. A phase 3 randomized, open-label study of nivolumab (ANTI-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. Ann. Oncol. 2014, 25(Suppl. 4):v1.
53. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
54. Herbst R.S., et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J. Clin. Oncol. 2013, 31(Suppl.):A3000.
55. Hamid O., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J. Clin. Oncol. 2013, 31(Suppl.):A9010.
56. Soria J.C., et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur. J. Cancer 2013, 49(Suppl. 2):A3408.
57. Powles T., et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J. Clin. Oncol. 2014, 32(Suppl.):A5011.
58. Segal N.H., et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J. Clin. Oncol. 2014, 32(Suppl.):A3002.
59. Jia M., et al. Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. J. Thorac. Dis. 2015, 7:455-461.
60. Powles T., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
61. Curran M.A., et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:4275-4280.
62. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
63. Sznol M., et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J. Clin. Oncol. 2014, 32(Suppl.):LBA9003.
64. Eggermont A.M. Therapeutic vaccines in solid tumours: can they be harmful?. Eur. J. Cancer 2009, 45:2087-2090.
65. Le D.T., et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 2013, 36:382-389.
66. Gibney G.T., et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin. Cancer Res. 2015, 21:712-720.
67. Lutz E.R., et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol. Res. 2014, 2:616-631.
68. Cipponi A., et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 2012, 72:3997-4007.
69. Dieu-Nosjean M.C., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 2008, 26:4410-4417.
70. + T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16723-16728.
71. Weide B., et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin. Cancer Res. 2014, 20:1601-1609.
72. Snyder A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371:2189-2199.
73. Alexandrov L.B., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
74. Boussiotis V.A. Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371:2230-2232.
75. Gubin M.M., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581.
76. Twyman-Saint Victor C., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520:373-377.
77. Cooper Z.A., et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res. 2014, 2:643-654.
78. Crittenden M., et al. Current clinical trials testing combinations of immunotherapy and radiation. Semina. Radiat. Oncol. 2015, 25:54-64.
79. Balachandran V.P., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 2011, 17:1094-1100.
80. von Minckwitz G., et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res. 2008, 10:R30.
81. Hutchings M., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52-59.
82. Eisenhauer E.A., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45:228-247.
83. Little R.F., et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 2006, 107:4650-4657.
84. Weber J.S., et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 2008, 26:5950-5956.
85. Di Giacomo A.M., et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol. Immunother. 2009, 58:1297-1306.
86. Wolchok J.D., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical cancer Res. 2009, 15:7412-7420.
87. + CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol. Res. 2013, 1:229-234.
88. Weber J.S., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncology 2013, 31:4311-4318.
89. Xu C., et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014, 25:590-604.
90. Green M.R., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116:3268-3277.
91. Taube J.M., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014, 20:5064-5074.
92. Martin-Liberal J., et al. Safety of pembrolizumab for the treatment of melanoma. Expert Opin. Drug Saf. 2015, 14:957-964.
93. Robert C., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
94. Choi J.N. Dermatologic adverse events to chemotherapeutic agents. Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Semin. Cutan. Med. Surg. 2014, 33:40-48.
95. Ibrahim R.A., et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J. Clin. Oncol. 2011, 29(Suppl.):A8583.
96. Thumar J.R., Kluger H.M. Ipilimumab: a promising immunotherapy for melanoma. Oncology 2010, 24:1280-1288.
97. Fecher L.A., et al. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013, 18:733-743.
98. Weber J.S., et al. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 2012, 30:2691-2697.
99. Downey S.G., et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 2007, 13:6681-6688.
100. Maker A.V., et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 2006, 29:455-463.
101. Ku G.Y., et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010, 116:1767-1775.
102. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol. Immunother. 2009, 58:823-830.
103. Zhang P., et al. Prevention of GVHD without losing GVL effect: windows of opportunity. Immunol. Res. 2011, 49:49-55.
104. Simpson T.R., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013, 210:1695-1710.